Table 1.
Ingenuity pathway analysis for functional analysis of the mapped biological functions and/or disease categories and canonical pathways for proteins in peripheral blood mononuclear cells.
| Top canonical pathways | p-value |
|---|---|
| Name | |
| Protein Ubiquitination Pathway | 1.46E-03 |
| IL-1 Signaling | 2.99E-03 |
| Ketolysis | 8.07E-03 |
| Ketogenesis | 8.96E-03 |
| Mevalonate Pathway I | 1.16E-02 |
| Top upstream regulators | |
| Upstream regulator | |
| 5-fluorouracil | 4.71E-5 |
| dichlorovinylcysteine | 3.14E-04 |
| ST1926 | 4.05E-04 |
| CD 437 | 8.03E-04 |
| CREB-NFkB | 9.09E-04 |
| Top disease and bio functions | |
| Diseases and disorders | |
| Metabolic Disease | 2.14E-02–1.15E-05 |
| Cancer | 4.32E-02–1.60E-05 |
| Hematological Disease | 4.32E-02–1.60E-05 |
| Immunological Disease | 4.32E-02–1.60E-05 |
| Organismal Injury and Abnormalities | 4.32E-02–1.60E-05 |
| Molecular and cellular functions | |
| Lipid Metabolism | 3.45E-02–2.75E-05 |
| Nucleic Acid Metabolism | 1.16E-02–8.99E-05 |
| Small Molecule Biochemistry | 2.14E-02–8.99E-04 |
| Cellular Movement | 2.14E-02–8.99E-04 |
| Cell Death and Survival | 3.89E-02–8.99E-04 |
| Top Networks | Score |
| ID Associated Network Functions | |
| 1. Developmental Disorder, Hereditary Disorder, Metabolic disease | 28 |
| 2. Behavior, Nervous System Development and Function, Cell-To-Cell Signaling and Interaction | 19 |
19 proteins showed significant differential direction of expression in fluoxetine responder and non-responder mice, e.g., overexpressed in one condition and under expressed in the other.